GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » 3-Year Dividend Growth Rate

US Stem Cell (US Stem Cell) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell 3-Year Dividend Growth Rate?

US Stem Cell's Dividends per Share for the three months ended in Dec. 2022 was $0.00.

The historical rank and industry rank for US Stem Cell's 3-Year Dividend Growth Rate or its related term are showing as below:

USRM's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 14.5
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

US Stem Cell's Dividend Payout Ratio for the three months ended in Dec. 2022 was 0.00. As of today, US Stem Cell's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of US Stem Cell's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, US Stem Cell's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Stem Cell's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where US Stem Cell's 3-Year Dividend Growth Rate falls into.



US Stem Cell 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


US Stem Cell  (OTCPK:USRM) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

US Stem Cell's Dividend Payout Ratio for the quarter that ended in Dec. 2022 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2022 )/ EPS without NRI (Q: Dec. 2022 )
=0/ -0.001
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Stem Cell 3-Year Dividend Growth Rate Related Terms>


US Stem Cell (US Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines

From GuruFocus

USRM Chief Science Officer Featured on One Radio Network

By PRNewswire PRNewswire 01-15-2019

Stem Cells Shows Promise For Repairing Torn Meniscus

By PRNewswire PRNewswire 07-10-2018

U.S. Stem Cell Reports First Quarter Results

By PRNewswire PRNewswire 05-10-2018

U.S. Stem Cell Confirms Date for Appeals Court Oral Arguments

By ACCESSWIRE ACCESSWIRE 09-30-2020

USRM Posts Increase in Revenue and Profit Margin for 2018

By PRNewswire PRNewswire 03-14-2019

Northstar Biotech and USRM BOD Members Reinvest in the Company

By ACCESSWIRE ACCESSWIRE 02-23-2021

USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

By PRNewswire PRNewswire 11-08-2018